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Introduction
 Tumor progression and metastasis depend 
on factors intrinsic to the tumor cell such 
as growth factors/receptors, extracellular 
matrix proteins, proteases, chemokines, 
and cellular adhesion molecules, as well as 
host factors. Cellular adhesion molecules 
are important in various biologic processes, 
including organogenesis, tissue homeosta-
sis, wound healing, and inflammatory/im-
mune responses.?? Adhesion molecules are 
expressed on the cell surface and can bind to 
themselves or other surface molecules. They 
mediate adhesion between cells of the same 
type or of different types and support tumor 
cell survival during extravasation, dissemi-
nation, mechanical arrest in capillaries, and 
intravasation. 
 Among the most important adhesion mol-
ecules implicated in metastasis are the integ-
rins, heterodimeric transmembrane receptors 
found throughout metazoan development.?? 
Most integrins bind to components of the 
extracellular matrix (ECM) such as laminins, 
collagens, and fibronectin. Integrins are in-
volved in various aspects of cellular behavior 
including stable adhesion to basement mem-
branes, formation of extracellular matrices 
and migration on such matrices, the forma-
tion of platelet aggregates, the establishment 
of intercellular junctions in the immune sys-
tem, and the support of bacterial and viral 
entry during infectious diseases.??
 The initiation and progression of cancer is 
accompanied by alterations in the expression 
of adhesion molecules, including integrins. 
Integrin-mediated migration and interac-
tions with other cells such as endothelial cells 
contributes to tumor cell invasion and me-
tastasis. The integrin profile that promotes 
metastatic spread is often not the same as 
the profile that promotes the initial transfor-
mation and growth. During tumor progres-
sion tumor cells gain and loose expression of 
specific integrins depending on the environ-
mental restraints encountered.
 While molecular parameters of the general 
metastatic process continue to be elucidated, 
much less is known about those involved in 
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Abstract?The finding that integrin α2 expression on tumor cells confers increased 
metastatic potential to certain tissue sites via direct physical adhesion, as well as the 
finding of the activation of an  intracellular signaling cascade linked to integrin α2 
that yields an invasion and growth phenotype is novel.  These findings can poten-
tially be exploited to increase our knowledge of which patients are at higher risk of 
forming (hepatic) metastases, thus aiding our ability to discriminate proper adjuvant 
therapy based on molecular phenotyping.  Additionally, expression of this cell surface 
molecule may be blocked, or the internal signaling cascade that results from binding 
of this cell surface molecule may be blocked to potentially decrease the metastatic po-
tential of cancers in a therapeutic fashion.
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organ-specific metastases. The liver is one 
of the most important targets for organ 
specific metastasis in many cancer types 
and is commonly the sole site of metastasis 
for gastrointestinal cancers. While a few 
studies have identified potential molecular 
correlates of hepatic metastasis, none have 
directly demonstrated their role in selective 
metastasis to the liver. In order to define cell 
membrane molecules mediating liver metas-
tasis, we employed the classic approach of re-
petitive in vivo metastasis selection to derive 
liver-metastasizing sublines of a tumor with 
normally low intrinsic potential for hepatic 
metastasis. Analysis of a broad array of cell 
membrane adhesion molecules and chemokine 
receptors revealed that the integrin α2 
(CD49b) was uniquely upregulated relative 
to the non-liver metastasizing parental line. 
Antibody blockade and forced expression of 
integrin α2 demonstrated a direct role in liver 
metastasis, collagen type IV binding and col-
lagen type IV-dependent activation of Focal 
adhesion kinase (FAK), a critical intracellu-
lar kinase involved in the metastatic process. 
Analysis of primary and metastatic colon 
tumors from patients provided evidence that 
integrin α2 plays a role in liver metastasis in 
human cancer.
Results
In vivo selection of liver metastasizing subline 
of B16 melanoma
 B16-F0 melanoma cells were subjected to 8 
rounds of in vivo selection for liver metasta-
sis using an intrasplenic injection route. This 
route favors hepatic metastasis since the 
splenic veins drain into the portal vein. None-
the-less, intrasplenic injection of B16-F0 gen-
erates very few hepatic metastases; instead 
demonstrating massive peritoneal dissemina-
tion. A rare liver metastasis was explanted 
and expanded in vitro followed by intrasplen-
ic re-administration (Fig. 1). After four (B16-
KY4) and eight rounds of selection (B16-KY8), 
tumor lines were established. B6 mice were 
challenged with four different tumor lines 
(B16-F0, B16-KY4, B16-KY8 and B16-F10, a 
subline selected for lung metastatic potential) 
in the hepatic metastasis model. Mice chal-
lenged with B16-F0 and B16-F10 had marked 
peritoneal dissemination of their disease and 
relatively small disease burden in the liver. In 
striking contrast, mice challenged with B16-
KY8 had significant disease burden in the 
liver with little peritoneal dissemination. 
Assessment of cell surface molecule expres-
sion associated with liver metastasis
 The four B16 cell lines were analyzed by 
flow cytometry to survey a broad panel of 
adhesion molecules potentially relevant to 
differential patterns of adhesion, attach-
ment, implantation, and growth. Of over 30 
molecules analyzed, including chemokine re-
ceptors previously implicated in hepatic hom-
ing, only integrin α2 (also known as CD49b) 
was differentially expressed on B16-KY8 
cells relative to the other three B16 cell lines. 
Because integrin α2 combines in a heterodi-
meric complex with integrin β1 (also known 
as CD29) to form VLA2, we also performed 
flow cytometric assays to test differences in 
expression of integrin β1. Consistent with the 
reported ubiquitous expression of integrin 
β1, the four B16 cell lines expressed similar 
amounts of integrin β1 (data not shown) but 
only the B16-KY8 cell line expressed higher 
amounts of integrin α2 (Fig. 2).
 In order to further determine whether 
integrin α2 was correlated with liver meta-
static potential, B16-KY8 cells were sorted 
into two populations: integrin α2 high and 
low expressing cells. These cells were then 
Fig. 1  Mice challenged with the parental 
B16-F0 had very few liver metastases 
with peritoneal dissemination. Mice 
challenged with B16-KY8 had mostly 
hepatic metastases.
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used to challenge mice in the intrasplenic in-
jection model and then sacrificed on day 21. 
When the integrin α2 high cells were used, 
30% of mice had limited peritoneal disease. In 
contrast, 100% of mice receiving intrasplenic 
injection of the integrin α2 low cells developed 
peritoneal dissemination. While, 100% of mice 
in both groups developed hepatic metastases, 
the number of nodules in the liver was signif-
icantly higher with the integrin α2 high than 
the one from mice injected integrin α2 low 
B16-KY8 cells. At the same time, the number 
of peritoneal nodules in the integrin α2 high 
injected mice was much less than the number 
in the integrin α2 low. These results provided 
initial evidence that integrin α2 expression 
might indeed enhance formation of liver me-
tastasis.
Integrin α2 blockade inhibits hepatic metasta-
sis while forced expression promotes selective 
hepatic metastasis
 In order to definitively determine whether 
integrin α2 expression was functionally in-
volved in hepatic metastasis, the effect of 
blocking B16-KY8 cells with anti-integrin α2 
antibody in the hepatic metastasis model was 
studied. While treatment of B16-KY8 cells 
by blocking with anti-integrin α2 antibody 
did not completely eliminate hepatic metas-
tasis, it was significantly reduced relative to 
treatment with the isotype control antibody. 
Importantly, anti-integrin α2 antibody treat-
ment concomitantly increased peritoneal dis-
semination of B16-KY8, demonstrating that 
integrin α2 blockade did not reduce generic 
metastatic potential but rather shifted me-
tastasis away from the liver. As a compari-
son group in this experiment, mice injected 
with B16-F0 cells, which express integrin α2 
on <3% of the cells, displayed peritoneal car-
cinomatosis with <30% showing evidence of 
(small volume) hepatic metastases. To further 
demonstrate that integrin α2 can promote 
selective hepatic metastasis, we transfected 
B16-F0 with the integrin α2 gene to gener-
ate the B16-SKY line and confirmed surface 
expression of integrin α2 by flow cytometry. 
We used B16-SKY to challenge mice by both 
intrasplenic and intravenous routes. After 
intrasplenic injection, B16-SKY produced sig-
nificantly more hepatic metastastic nodules 
than B16-F0. We also studied the effect of 
blocking integrin α2 expression on B16-SKY 
on the pattern of metastases after intrasplen-
ic and tail vein injection. The most notable 
effect of blocking integrin α2 expression on 
B16-SKY in the hepatic metastasis model was 
to increase the rate of peritoneal metastases 
though there was additionally a decrease in 
liver metastases. 
Integrin α2 expression enhances binding to col-
lagen type IV and mediates FAK activation 
upon collagen type IV binding
 Integrins are known to mediate collagen 
binding and the liver in particularly rich in 
type IV collagen. We therefore asked wheth-
er integrin α2 up-regulation might enhance 
collagen type IV binding and whether there 
is binding mediated activation of kinases 
known to be involved in metastasis. To study 
the intensity of attachment of the B16 cell 
lines to collagen type IV coated plates, which 
is a known ligand of integrin α2, an attach-
ment assay was performed using B16-F0 and 
B16-KY8. The B16-F0 group displayed low 
numbers of attached tumor cells on the col-
lagen type IV coated plate. In contrast, the 
B16-KY8 group displayed a >6 fold increase 
Fig. 2  Analysis of integrins α2 reveals that integrin α2 is selectively upregulated 
in B16-KY8.
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in attachment of tumor cells on the collagen 
type IV coated plates. 
 We next determined whether integrin α2 
dependent binding to collagen type IV medi-
ated activation of FAK in tumor cells. As de-
scribed above, FAK, which plays a major role 
in cell motility, has been shown to be activat-
ed by engagement of a number of integrins, 
including integrin α2, and is thought to be an 
important factor in the metastatic process. 
Indeed, attachment of B16-KY8 and B16-SKY 
to collagen type IV coated plates resulted in 
significant FAK activation, peaking at 90 
minutes, whereas B16-F0 cells plated on col-
lagen IV failed to activate FAK. FAK activa-
tion was collagen IV dependent and specific, 
since another kinase involved in metabolic 
regulation of tumor cells, AKT, was equally 
activated in B16-F0, KY8 or SKY and was 
not affected by binding to collagen IV. Taken 
together, these studies demonstrate that in-
duction of integrin α2 results in collagen IV 
dependent FAK activation and provide a po-
tential mechanistic basis for its role in medi-
ating selective hepatic metastasis.
Correlation between integrin α2 expression and 
hepatic metastasis in human colorectal cancer
 We also analyzed colorectal tumors from 
patients with simultaneous liver and lung 
metastases. Metastases are significantly less 
infiltrated with leukocytes than primary 
colorectal tumors, allowing direct analysis 
of Integrin α2 on tumor cells by immunohis-
tochemical staining. Sections of concurrent 
liver and lung metastases available from 
seven colorectal cancer patients were stained 
with anti-integrin α2 antibody and processes 
for immunohistochemistry as described. In 
six of seven cases, the liver metastases had 
higher levels of staining than the pulmonary 
metastases. In roughly half the cases, hepatic 
metastases showed extremely strong staining 
for Integrin α2, whereas the corresponding 
lung metastases had extremely low staining. 
These results in both primary and metastatic 
human colorectal cancers show a correlation 
between integrin α2 expression and propen-
sity to metastasize to the liver.
Discussion
 The formation of metastatic disease from 
a tumor primary requires multiple complex 
steps including invasion through the normal 
tissue architecture, intravasation, arrest, 
extravasation, and growth. Many of theses 
processes have been associated with the up-
regulation of various cell surface molecules, 
and in particular integrins.??
 We used in vivo selection to derive a B16 
cell line (B16-KY8) that has a higher propen-
sity to form hepatic metastases and lower 
propensity to form peritoneal metastases 
than the parental cell line (B16-F0) in both 
a hepatic metastasis (splenic injection) and 
a pulmonary (tail vein injection) model. We 
hypothesized that differential expression of 
one or more cell surface molecules would be 
responsible for this difference in metastatic 
pattern. Remarkably, analysis of a broad 
panel of integrins, chemokine receptors previ-
ously implicated in liver homing and cellular 
adhesion molecules revealed a single mole-
cule, integrin α2, that was differentially ex-
pressed between the non-liver metastasizing 
parental B16-F0 tumor and the liver metas-
tasizing B16-KY8. Multiple complimentary 
approaches, including sorting of high vs. low 
expressers, antibody blockade and forced ex-
pression via transfection, demonstrated that 
integrin α2 plays a causal role in liver metas-
tasis. Analysis of both primary and meta-
static human colorectal cancers demonstrated 
an association between integrin α2 expression 
and liver metastasis, suggesting that inte-
grin α2 is relevant to the liver-specificity of 
metastasis in human cancer. Mechanistically, 
in vitro studies suggested that integrin α2 
may facilitate hepatic metastasis via binding 
to collagen type IV and consequent activa-
tion of FAK. With this information in our 
murine system, we studied integrin α2 expres-
sion in two different sets of patient samples. 
In the first set, primary colorectal cancers 
were selected and divided into patients with 
and without hepatic metastases. We found 
that the patients with hepatic metastases had 
higher expression of integrin α2 mRNA in the 
microdissected tumor cells compared to those 
patients without hepatic metastases. In the 
second set, we studied matched hepatic and 
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pulmonary metastases from patients with 
colorectal cancer. In two cases we also had 
the matched primary specimens. We found 
increased cell surface expression of the inte-
grin α2 protein on the cell surface of tumor 
cells in hepatic metastases compared to pul-
monary metastases. 
Integrin α2β1 also known as very late antigen 
2 (VLA2) is primarily found on activated T 
cells, platelets, and have been described on 
epithelial cells such as keratinocytes.?? Inter-
estingly on keratinoyctes, VLA2 is consid-
ered a differentiation marker. Upon terminal 
differentiation, keratinocytes not only lose 
their contacts to the basement membrane, 
but also decrease their expression of VLA2 
drastically.?? The expression of the other two 
collagen-binding integrins, α10β1 and α11β1, is 
more restricted to chondrocytes and fibro-
blasts, respectively.????
 Integrin α2β1 can bind with collagen type I, 
II, and IV.??10? Collagen type I is found pri-
marily in bone, dermis, tendon, ligaments, 
and cornea. Collagen type II is found primar-
ily in cartilage, vitreous body, and nucleus 
pulposus. Collagen type IV is found primar-
ily in basement membranes.11? In our murine 
models of hepatic, pulmonary, and peritoneal 
metastases, collagen type IV, which is highly 
enriched in the liver, is the most relevant col-
lagen subtype to implicate in an integrin-
collagen interaction. 
 Although a number of studies have impli-
cated integrin expression in the metastatic 
process, including liver metastases, the find-
ings presented here are the first to directly 
demonstrate a role for integrin α2 in selective 
liver metastsis. A few reports have impli-
cated α6 integrins (associated with various 
β subunits), which bind laminin, in liver me-
tastases.12?13?14? The most convincing report 
demonstrated that both components of a 
complex of integrin α6β2 and the D6.1A tet-
raspanin were necessary for liver metastasis 
in a rat pancreatic adenocarcinoma model.15? 
Other adhesion molecules, including integrin 
αvβ3, osteopontin (a ligand for integrin αvβ3), 
integrin αvβ5, integrin α4β1 and VCAM-1 have 
been associated with liver metastasis in vari-
ous models,16-20? but their direct role has not 
been comprehensively confirmed by blockade 
and overexpression analyses, nor compara-
tive expression analysis in human tumors as 
we have done for integrin α2 in the current 
report.
 While this is the first report to implicate 
integrin α2 in hepatic metastasis, 2 earlier 
studies have shown that integrin α2 plays a 
role in the intrahepatic migration of tumor 
cells. One report showed that chemotactic and 
haptotactic migration of hepatocellular carci-
noma cells in response to growth factors pro-
duced in a fibrotic microenvironment involves 
integrin α2.21? A second report showed that 
while integrin α2 did not affect extravasation 
of rhabdomyosarcoma cells in the liver, it fa-
cilitated their intrahepatic migration to the 
subcapsular space once in the liver parenchy-
ma. It remains to be determined whether the 
collagen IV-dependent, FAK-mediated role of 
integrin α2 in hepatic metastasis suggested in 
the current report also applies to its capacity 
to enhance intrahepatic migration of tumor 
cells.
 The link between integrins and intracel-
lular signaling molecules involved in cell mi-
gration, such as FAK, is an emerging theme 
in metastasis research.22? Of note, a protein 
tyrosine phosphatase that affects cell motil-
ity, PRL-3, has been implicated in enhanced 
metastatic potential of colon cancer.23?24? 
Whether PRL-3 specifically enhances liver 
metastasis is unclear, since it was equivalent-
ly up regulated in metastases from multiple 
organs.25? This contrasts with our findings 
in animal models that integrin α2 expression 
did not significantly enhance lung metasta-
sis after intravenous injection of tumors and 
was expressed at lower levels in lung vs. liver 
metastasis of human colon cancer. Whether 
there is a direct link between integrin α2 and 
PRL-3 remains to be determined.
 In summary, we have provided direct evi-
dence in murine models and correlative evi-
dence in human tumors that integrin α2β1 is 
one of the determinants conferring potential 
for selective hepatic metastastatis. We hy-
pothesize that integrin α2 expression may be 
particularly important for liver metastases 
in tumors whose primary venous drainage 
flows through the liver, such as gastrointes-
tinal cancers. In this circumstance, integrin 
α2 would putatively engage collagen type IV 
in the liver, facilitating arrest of tumor cells 
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and FAK activation, which in turn effects 
cell motility changes that would facilitate 
metastatic distribution within the liver pa-
renchyma. 
 This finding has both prognostic and 
therapeutic significance. Analysis of integrin 
α2 in primary tumors may help determine 
which patients are at higher risk for form-
ing hepatic metastases. Additionally, there 
is potential to block the formation of hepatic 
metastases in patients who are discovered to 
have colorectal cancer and who have expres-
sion of integrin α2 in their resected prima-
ries. This therapy could potentially be used 
from the time of diagnosis immediately after 
colonoscopic biopsy, through the period of 
surgical therapy in which the primary was 
removed, and immediately after in the ad-
juvant setting. The possibility of decreasing 
the hepatic recurrence rate of patients who 
have undergone curative resection of hepatic 
colorectal metastases would need to be ex-
plored. 
References
?? Koukoulis, G.K., Patriarca, C. and Gould, 
V.E.: Adhesion molecules and tumor me-
tastasis. Hum. Pathol., 29?889-892, 1998. 
?? Hynes, R.O. and Zhao, Q.: The evolution 
of cell adhesion. J. Cell Biol., 150?F89-
96, 2000.
?? Danen, E.H.: Integrins: regulators of 
tissue function and cancer progression. 
Curr. Pharm. Des., 11?881-891, 2005.
?? Cairns, R.A., Khokha, R. and Hill, R.P. 
: Molecular mechanisms of tumor inva-
sion and metastasis: an integrated view. 
Curr. Mol. Med., 3?659-671, 2003.
?? Santoro, S.A. and Zutter, M.M.: The alpha 
2 beta 1 integrin: a collagen receptor on 
platelets and other cells. Thromb. Hae-
most., 74?813-821, 1995.
?? Watt, F.M.: Role of integrins in regu-
lating epidermal adhesion, growth and 
differentiation. EMBO J., 21?3919-3926, 
2002. 
?? Camper, L., Hellman, U. and Lundgren-
Akerlund, E.: Isolation, cloning, and se-
quence analysis of the integrin subunit 
alpha10, a beta1-associated collagen bind-
ing integrin expressed on chondrocytes. 
J. Biol. Chem., 273?20383-20389, 1998. 
?? Velling, T., Kusche-Gullberg, M., Sejer-
sen, T. and Gullberg, D.: cDNA cloning 
and chromosomal localization of human 
alpha(11) integrin: A collagen-binding, 
I domain-containing, beta(1)-associated 
integrin alpha-chain present in muscle 
tissues. J. Biol. Chem., 274?25735-25742, 
1999. 
?? Eble, J.A.: Collagen-binding integrins as 
pharmaceutical targets. Curr. Pharm. Des., 
11?867-880, 2005.
10? White, D.J., Puranen, S., Johnson, M.S. 
and Heino, J.: The collagen receptor sub-
family of the integrins. Int. J. Biochem. 
Cell Biol., 36?1405-1410, 2004.
11? Gelse, K., Poschl, E. and Aigner, T.: Col-
lagens--structure, function, and biosyn-
thesis. Adv. Drug Deliv. Rev., 55?1531-
1546, 2003.
12? Sawai, H., Funahashi, H., Yamamoto, M., 
Okada, Y., Hayakawa, T., Tanaka, M., 
Takeyama, H. and Manabe, T.: Inter-
leukin-1alpha enhances integrin alpha(6)
beta(1) expression and metastatic capa-
bility of human pancreatic cancer. Oncol-
ogy, 65?167-173, 2003.
13? Yamaguchi, K., Ura, H., Yasoshima, T., 
Shishido, T., Denno, R. and Hirata, K.: 
Liver metastatic model for human gas-
tric cancer established by orthotopic 
tumor cell implantation. World J. Surg., 
25?131-137, 2001.
14? Kemperman, H., Driessens, M.H., La 
Riviere, G., Meijne, A.M. and Roos, E.: 
Adhesion mechanisms in liver metastasis 
formation. Cancer Surv., 24?67-79, 1995. 
15? Herlevsen, M., Schmidt, D.S., Miyazaki, 
K. and Zoller, M.: The association of the 
tetraspanin D6.1A with the alpha6beta4 
integrin supports cell motility and liver 
metastasis formation. J. Cell Sci., 116?
4373-4390, 2003. 
16? Kikkawa, H., Kaihou, M., Horaguchi, 
N., Uchida, T., Imafuku, H., Takiguchi, 
A., Yamazaki, Y., Koike, C., Kuruto, 
R., Kakiuchi, T., et al.: Role of integrin 
alpha(v)beta3 in the early phase of liver 
metastasis: PET and IVM analyses. Clin. 
Exp. Metastasis, 19?717-725, 2002.
17? Nishimori, H., Yasoshima, T., Hata, F., 
Denno, R., Yanai, Y., Nomura, H., Tana-
Kiyoshi Yoshimura6
ka, H., Kamiguchi, K., Sato, N. and Hi-
rata, K.: A novel nude mouse model of 
liver metastasis and peritoneal dissemi-
nation from the same human pancreatic 
cancer line. Pancreas, 24?242-250, 2002.
18? Kishimoto, H., Sasahara, K., Yamazaki, 
K., Nagata, T., Uotani, H., Yamashita, I., 
Tauchi, K. and Tsukada, K.: Obstructive 
jaundice facilitates hepatic metastasis of 
B16F1 mouse melanoma cells: participa-
tion of increased VCAM-1 expression in 
the liver. Oncol. Rep., 8?575-578, 2001. 
19? Papadimitriou, M.N., Menter, D.G., Kon-
stantopoulos, K., Nicolson, G.L. and McIn-
tire, L.V.: Integrin alpha4beta1/VCAM-
1 pathway mediates primary adhesion of 
RAW117 lymphoma cells to hepatic sinu-
soidal endothelial cells under flow. Clin. 
Exp. Metastasis, 17?669-676, 1999.
20? Wai, P.Y., Mi, Z., Guo, H., Sarraf-Yazdi, S., 
Gao, C., Wei, J., Marroquin, C.E., Clary, 
B. and Kuo, P.C.: Osteopontin silencing 
by small interfering RNA suppresses in 
vitro and in vivo CT26 murine colon ade-
nocarcinoma metastasis. Carcinogenesis, 
26?741-751, 2005.
21? Yang, C., Zeisberg, M., Lively, J.C., Ny-
berg, P., Afdhal, N. and Kalluri, R.: Inte-
grin alpha1beta1 and alpha2beta1 are the 
key regulators of hepatocarcinoma cell 
invasion across the fibrotic matrix mi-
croenvironment. Cancer Res., 63?8312-
8317, 2003. 
22? Steeg, P.S.: Metastasis suppressors alter 
the signal transduction of cancer cells. 
Nat. Rev. Cancer, 3?55-63, 2003. 
23? Saha, S., Bardelli, A., Buckhaults, P., 
Velculescu, V.E., Rago, C., St. Croix, B., 
Romans, K.E., Choti, M.A., Lengauer, 
C., Kinzler, K.W. and Vogelstein, B.: A 
phosphatase associated with metastasis 
of colorectal cancer. Science, 294 : 1343-
1346, 2001.
24? Kato, H., Semba, S., Miskad, U.A., Seo, 
Y., Kasuga, M. and Yokozaki, H.: High 
expression of PRL-3 promotes cancer cell 
motility and liver metastasis in human 
colorectal cancer: a predictive molecular 
marker of metachronous liver and lung 
metastases. Clin. Cancer Res., 10?7318-
7328, 2004. 
25? Bardelli, A., Saha, S., Sager, J.A., Ro-
mans, K.E., Xin, B., Markowitz, S.D., 
Lengauer, C., Velculescu, V.E., Kinzler, 
K.W. and Vogelstein, B.: PRL-3 expres-
sion in metastatic cancers. Clin. Cancer 
Res., 9?5607-5615, 2003. 
Integrin alpha2 Mediates Hepatic Metastasis 7

